For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126 (Public Relations)
+81-3-6225-1125 (Investor Relations)
http://www.daiichisankyo.com/
Daiichi Sankyo Receives Approval to Manufacture and Market Inavir(R) Influenza Antiviral Inhalant for Treatment in Japan
Tokyo, Japan (September 10, 2010) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that it has received approval in Japan to manufacture and market Inavir® Dry Powder Inhaler 20mg, for treatment of influenza that is a laninamivir octanoate hydrate prodrug.
Inavir® is a long-acting neuraminidase inhibitor that Daiichi Sankyo developed for the Japanese market. Inavir® directly delivers the drug to the infected airways of influenza patients, and a single inhaled dose has proven to be as effective as a five-day course of oseltamivir for treatment of influenza. The company is confident that Inavir® will be an important alternative for treating influenza, both benefiting patients and contributing to society.
Daiichi Sankyo has a solid record in developing and selling antibacterial agents, and also offers influenza vaccines. Inavir® complements the company’s lineup for preventing and treating primary and secondary influenza infections.
Inavir® Overview
Product name |
Inavir® Dry Powder Inhaler 20mg |
Generic name |
Laninamivir (International Nonproprietary Names) |
Indication |
Treating influenza A and B viruses |
Dosage and Administration |
Adults: A single inhaled dose of 40 mg of laninamivir octanoate hydrate
Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate hydrate. If 10 years old or older, a single inhaled dose of 40 mg. |
Approval date |
September 10, 2010 |
End